Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 2
1999 2
2000 3
2001 1
2002 3
2003 4
2004 3
2005 3
2006 6
2007 5
2008 7
2009 5
2010 4
2011 6
2012 4
2013 6
2014 7
2015 11
2016 10
2017 6
2018 6
2019 7
2020 8
2021 7
2022 10
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Clinical promise of next-generation complement therapeutics.
Mastellos DC, Ricklin D, Lambris JD. Mastellos DC, et al. Nat Rev Drug Discov. 2019 Sep;18(9):707-729. doi: 10.1038/s41573-019-0031-6. Epub 2019 Jul 19. Nat Rev Drug Discov. 2019. PMID: 31324874 Free PMC article. Review.
Insight into mode-of-action and structural determinants of the compstatin family of clinical complement inhibitors.
Lamers C, Xue X, Smieško M, van Son H, Wagner B, Berger N, Sfyroera G, Gros P, Lambris JD, Ricklin D. Lamers C, et al. Nat Commun. 2022 Sep 20;13(1):5519. doi: 10.1038/s41467-022-33003-7. Nat Commun. 2022. PMID: 36127336 Free PMC article.
Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/AMY-101). ...Our study may thereby guide the application of existing and development of next-generation compstatin analogs....
Moreover, compstatin derivatives with enhanced pharmacodynamic and pharmacokinetic profiles are in clinical development (e.g., Cp40/A …
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.
Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, Tektonidou M, Konstantinidis T, Papagoras C, Mitroulis I, Germanidis G, Lambris JD, Ritis K. Skendros P, et al. J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374. J Clin Invest. 2020. PMID: 32759504 Free PMC article. Clinical Trial.
COVID-19 serum induced complement activation in vitro, consistent with high complement activity in clinical samples. Complement C3 inhibition with compstatin Cp40 disrupted TF expression in neutrophils. In conclusion, we provide a mechanistic basis for a pivotal role of co …
COVID-19 serum induced complement activation in vitro, consistent with high complement activity in clinical samples. Complement C3 inhibitio …
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
Skendros P, Germanidis G, Mastellos DC, Antoniadou C, Gavriilidis E, Kalopitas G, Samakidou A, Liontos A, Chrysanthopoulou A, Ntinopoulou M, Kogias D, Karanika I, Smyrlis A, Cepaityte D, Fotiadou I, Zioga N, Mitroulis I, Gatselis NK, Papagoras C, Metallidis S, Milionis H, Dalekos GN, Willems L, Persson B, Manivel VA, Nilsson B, Connolly ES, Iacobelli S, Papadopoulos V, Calado RT, Huber-Lang M, Risitano AM, Yancopoulou D, Ritis K, Lambris JD. Skendros P, et al. Sci Adv. 2022 Aug 19;8(33):eabo2341. doi: 10.1126/sciadv.abo2341. Epub 2022 Aug 17. Sci Adv. 2022. PMID: 35977025 Free PMC article.
Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.
Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD. Mastellos DC, et al. Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Eur J Clin Invest. 2015. PMID: 25678219 Free PMC article. Review.
Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement-based inhibitors. Compstatin was discovered as a cyclic peptide that inhibits complement activation by binding C3 and interfering wit …
Indeed, the introduction of the first complement-targeting drugs has reignited a vibrant interest in the clinical translation of complement- …
Innate immune responses to trauma.
Huber-Lang M, Lambris JD, Ward PA. Huber-Lang M, et al. Nat Immunol. 2018 Apr;19(4):327-341. doi: 10.1038/s41590-018-0064-8. Epub 2018 Mar 5. Nat Immunol. 2018. PMID: 29507356 Free PMC article. Review.
Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.
Qu H, Magotti P, Ricklin D, Wu EL, Kourtzelis I, Wu YQ, Kaznessis YN, Lambris JD. Qu H, et al. Mol Immunol. 2011 Jan;48(4):481-9. doi: 10.1016/j.molimm.2010.10.004. Epub 2010 Nov 9. Mol Immunol. 2011. PMID: 21067811 Free PMC article.
Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation of the human complement system. Compstatin and its derivatives have shown great promise for the treatment of many clinical disorders associated with unbalanced complement
Compstatin is a 13-residue disulfide-bridged peptide that inhibits a key step in the activation of the human complement system. Co
Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation.
Nilsson B, Larsson R, Hong J, Elgue G, Ekdahl KN, Sahu A, Lambris JD. Nilsson B, et al. Blood. 1998 Sep 1;92(5):1661-7. Blood. 1998. PMID: 9716594 Free article.
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...These data show that complement activation, leading to activation and binding of PMNs to the biomaterial surface, can be abolished by the additi
Compstatin effectively inhibited the generation of C3a and sC5b-9 and the binding of C3/ C3 fragments to the polymer surface. ...Thes
Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
Hajishengallis G, Kajikawa T, Hajishengallis E, Maekawa T, Reis ES, Mastellos DC, Yancopoulou D, Hasturk H, Lambris JD. Hajishengallis G, et al. Front Immunol. 2019 Mar 12;10:406. doi: 10.3389/fimmu.2019.00406. eCollection 2019. Front Immunol. 2019. PMID: 30915073 Free PMC article. Review.
Application of the C3 inhibitor compstatin in a human whole blood model designed for complement research - 20 years of experience and future perspectives.
Mollnes TE, Storm BS, Brekke OL, Nilsson PH, Lambris JD. Mollnes TE, et al. Semin Immunol. 2022 Jan;59:101604. doi: 10.1016/j.smim.2022.101604. Epub 2022 May 13. Semin Immunol. 2022. PMID: 35570131 Free article. Review.
For instance, to examine the relative roles of C3 and C5 in complement activation, it is possible to compare the effects of the C3 inhibitor compstatin effects to those of inhibitors of C5 and C5aR1. We also discuss how complement is activated by both pathogen-associated m …
For instance, to examine the relative roles of C3 and C5 in complement activation, it is possible to compare the effects of the C3 inhibitor …
125 results